Memorel

Memantine Hydrochloride

Method of action: Psychoanaleptics

Treatment option: Dementia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Memorel

Property	Description
Active ingredient	Memantine Hydrochloride
Form	Film-coated tablets, Oral solution
Pharmacological class	NMDA Receptor Antagonist
Common use	Symptomatic management of dementia
Origin	Synthetic compound (Adamantane derivative)

What Type of Medicine is Memorel (Memantine Hydrochloride)?

Memorel is a prescription medicine defined by its active compound, Memantine Hydrochloride, which classifies it as a synthetic anti-dementia drug. It is a single-ingredient product belonging to the distinct pharmacological class of N-methyl-D-aspartate (NMDA) receptor antagonists. The underlying chemical structure is an adamantane derivative, a specific synthetic origin that guides its mechanism.

The core identity of Memantine is its function as a low-affinity, uncompetitive blocker of the NMDA receptor. This mechanism makes it distinct from other dementia treatments like cholinesterase inhibitors. Memantine is used in the management of certain types of cognitive decline by regulating excessive glutamatergic neurotransmission—a specific symptomatic strategy designed to address abnormal nerve cell activity.

Memorel's Available Preparations and General Purpose

Memorel is designed for oral administration and is supplied in two primary pharmaceutical preparations: film-coated tablets and an oral solution. Both formulations deliver the active Memantine Hydrochloride alongside necessary pharmaceutical excipients. The availability of an oral solution provides an alternative form that assists patient adherence, particularly in elderly patients who may experience difficulty swallowing solid medications.

The general purpose of the medicine is the symptomatic management and support of cognitive stability. It is used in situations involving moderate-to-severe dementia, helping to preserve or maintain certain mental functions and thereby supporting the functional capacity of patients in their daily routines.

Regulatory References

What side effects are possible with Memorel?

Memorel: Possible Side Effects and Safety Information

This section details the officially documented safety profile, adverse reactions, and regulatory restrictions associated with the active substance Memantine (assumed to be the substance in Memorel), based on governmental regulatory sources.

Adverse reaction scope

Key adverse reaction categories: Nervous system disorders (e.g., dizziness, headache, somnolence), Psychiatric disorders (e.g., hallucinations, confusion), Gastrointestinal disorders (e.g., constipation), and Vascular disorders (e.g., hypertension).
Frequency classification (based on regulatory frequency bands):
- Common (ge 1/100 to < 1/10): Dizziness, headache, constipation, somnolence, and hypertension.
- Uncommon (ge 1/1,000 to < 1/100): Fungal infections, confusion, hallucinations (primarily in severe Alzheimer's disease), gait abnormalities, and cardiac failure.
- Very Rare: Seizures.
System-organ classes involved: Primarily Nervous system, Gastrointestinal, Psychiatric, Vascular, Cardiac, and General disorders.
Serious adverse reactions (as documented in regulatory sources): Cardiac failure, seizures, venous thromboembolism (blood clots), and isolated post-marketing cases of pancreatitis and hepatitis. Alzheimer’s disease itself is associated with suicidal ideation, and these events have been reported in patients treated with the substance.
Population-specific safety considerations (if applicable): Use is not recommended in children and adolescents below 18 years due to insufficient data on efficacy and safety. Patients with severe renal impairment require a dose reduction.
Dose- or exposure-related patterns (if explicitly stated): Adverse reactions are less likely to occur if the dose is gradually increased over several weeks, rather than initiating the full maintenance dose immediately.
Safety-related restrictions or limitations: Caution is advised in patients with pre-existing conditions that may increase urine pH (e.g., drastic dietary changes, urinary tract infections by certain bacteria, renal tubulary acidosis), as this can affect drug elimination. Concomitant use with other NMDA-antagonists like amantadine is generally avoided due to the risk of central nervous system toxicity/psychosis.

Safety classifications (high-level)

Regulatory frequency framework used: Typically the EMA/ICH frequency bands (e.g., Common, Uncommon, Rare) as defined in the Summary of Product Characteristics (SmPC).
Regulatory basis (EMA / FDA / other government authority): Safety information is derived from regulatory product labeling reviewed by authorities such as the EMA and Health Canada, reflecting the formal understanding of risks.
Context-of-use safety notes (as defined in official documents): The ability to drive or operate machinery may be impaired due to the central nervous system effects (confusion, dizziness); patients are advised to assess their ability before engaging in such activities.

Resulting safety structure

Regulatory safety summary:

The most frequently reported side effects are generally mild to moderate and involve the central nervous system, such as dizziness and headache.
Serious, but less common, risks include cardiac failure and venous thromboembolism, alongside isolated reports of severe hepatic or pancreatic inflammation.
Safety monitoring is particularly required for patients with coexisting conditions affecting urine pH, severe kidney impairment, or those receiving specific interacting medicines (e.g., other NMDA-antagonists).

Connection to the overall safety profile (2–4 sentences): The official safety information structures the understanding of risks by categorizing adverse events predominantly affecting the nervous system as common, while placing severe organ-system effects into less frequent categories. The profile mandates careful consideration of pre-existing conditions that may alter drug exposure or increase susceptibility to specific serious reactions, such as cardiovascular or psychotic events. This formal framework highlights the need for physician monitoring, especially during the initial dosing period and in patients with underlying systemic conditions. The documentation serves as the essential technical basis for understanding the risk landscape.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Memantine Hydrochloride, the active ingredient in Memorel, is officially documented to primarily involve Central Nervous System (CNS) and gastrointestinal manifestations. The documented clinical signs include confusion, somnolence, agitation, and gait disturbance. Gastrointestinal effects such as vomiting and diarrhoea are also reported in regulatory labeling, even with doses not considered lethal.

In severe overdose cases, the manifestations can escalate to life-threatening outcomes. Regulatory reports list occurrences of psychosis, proconvulsiveness, stupor, and prolonged coma. Individuals who have collapsed, are experiencing a seizure, or cannot be awakened require immediate emergency attention. Regulatory guidance states that medical help must be sought right away if these severe or life-threatening symptoms are observed.

Treatment for an overdose is exclusively symptomatic and supportive. No specific pharmacological antidote is known to reverse the effects of Memantine. The officially described procedures to manage severe intoxication include administering activated charcoal (carbo medicinalis) or performing gastric lavage to remove the unabsorbed substance. Furthermore, due to the drug’s elimination pathway, patients with conditions that elevate urine pH, such as severe renal tubular issues, may face an increased risk of drug accumulation and potential toxicity.

Therapeutic Uses of Memorel

What Memorel Treats: Main Uses and Benefits

Memorel (Memantine Hydrochloride) is commonly used as part of symptomatic management for moderate-to-severe dementia, particularly in conditions characterized by periods of heightened symptoms associated with Alzheimer's disease. Its application is focused exclusively on providing support across cognitive, behavioral, and functional symptom domains during the illness. This application is relevant for managing symptoms that interfere with daily comfort.

The medication helps manage a variety of symptoms, including progressive memory loss, impaired thinking ability, general confusion, and associated agitation or mood disturbances. It is relevant in clinical scenarios where short-term symptomatic assistance is needed to address symptoms that interfere with daily comfort.

The symptomatic relief provided helps patients cope more steadily with symptom fluctuations, and contributes to easing the overall symptom load during periods of heightened discomfort. It is applied when groups of symptoms appear suddenly or fluctuate.

Quick Fact: Relief for Cognitive and Functional Decline Memorel is considered relevant for managing symptom clusters that may become intense or disruptive, and helps patients cope more steadily with symptom fluctuations, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

European Medicines Agency overview

Eligibility and Restrictions for Use

Who can and cannot use Memorel?

Memorel (Memantine Hydrochloride) eligibility is strictly defined by regulatory authorities based on population characteristics and pre-existing conditions.

Populations Allowed

Memorel is approved for use in adult patients aged 18 and over for the treatment of moderate-to-severe dementia. Use is well-established in the elderly population who were the primary focus of clinical studies.

Contraindications and Non-Eligibility

Memorel is contraindicated and must not be used if you have a known hypersensitivity or allergy to memantine hydrochloride or any excipients in the formulation.

The medicine is not recommended for use in children and adolescents under 18 due to a lack of available regulatory data on safety and efficacy in that age group.

Restricted and Conditional Use

Patients with severe renal (kidney) impairment are eligible for use but are subject to a conditional dose restriction established in the official labeling. Use in severe hepatic (liver) impairment is either not recommended or requires specific caution due to insufficient clinical information.

Special caution is advised for patients with a history of epilepsy or seizures, and for women during pregnancy and lactation, where use is often restricted or not recommended.

What should I know about interactions with other medicines?

The interaction profile for Memantine Hydrochloride is defined by its renal clearance pathway and its pharmacodynamic action, as documented in regulatory labeling.

Interactions Affecting Drug Exposure (Pharmacokinetic)

Memorel is partially eliminated via the renal cationic transport system. Co-administration with other substances that utilize this system, such as Cimetidine, Ranitidine, Quinidine, or Nicotine, may potentially alter its clearance and increase plasma concentrations. A more significant risk of drug accumulation is documented with agents that cause urine alkalization, including Carbonic Anhydrase Inhibitors and Sodium Bicarbonate, which can severely reduce Memantine clearance. No clinically significant interactions with CYP450 enzymes are expected.

Interactions Causing Additive Effects (Pharmacodynamic)

Regulatory authorities restrict the co-administration of Memorel with other N-methyl-D-aspartate (NMDA) receptor antagonists, such as Amantadine, Ketamine, and Dextromethorphan. This restriction is due to the potential for additive central nervous system effects. Furthermore, the effects of agents like L-dopa, Dopaminergic Agonists, Anticholinergics, and muscle relaxants like Dantrolene or Baclofen may be enhanced or modified when used concurrently.

Procedural Constraints

When Memorel is co-administered with oral anticoagulants, specifically Warfarin, close monitoring of the International Normalized Ratio (INR) is advised due to post-marketing reports of altered anticoagulant exposure. The drug's absorption is not affected by food. Caution is advised for use in patients with severe hepatic impairment due to potential clearance issues.

Mechanism of Action

Memorel operates by influencing specific biological systems and processes through distinct mechanistic domains, initiating mechanistic cascades that culminate in resulting physiological effects. Its action is centered on regulating overactive or dysregulated processes via targeted pathway adjustment.

Modulation of Receptor-Mediated Signaling

Memorel acts within domains involving receptor-mediated signaling to modify early molecular steps that shape systemic physiological outcomes. This domain covers the targets where specific neurotransmitters or mediators dominate, resulting in the quantitative reduction of mediator-induced pathway flux and contributing to the dampening of heightened physiological signaling output.

Regulation of Pathway Activity

The drug engages mechanisms that influence feedback regulation within pathways, specifically those associated with heightened physiological responses. By altering pathway activity that may escalate under certain conditions, Memorel promotes the establishment of baseline or reduced signaling metrics within targeted pathways, resulting in defined alterations to physiological measurements.

Dosage and Administration Information

Official Administration Guidelines

Memorel (Memantine Hydrochloride) is administered solely through the oral route in three principal pharmaceutical preparations: immediate-release tablets, extended-release capsules, and an oral solution.

Dosing Schedule and Frequency

The official usage protocol is defined by a structured, gradual titration schedule. The dose must be increased in small, label-specified increments, with a minimum interval of one week between adjustments, until the target maintenance dose is reached. For the immediate-release form, this typically progresses from a 5 mg starting dose to a 20 mg per day maintenance dose, which is usually administered twice daily. The extended-release capsule is administered once daily with a maximum labeled dose of 28 mg.

Administration Context and Constraints

The medicine is designed for flexibility and may be taken with or without food. Specific constraints govern its administration based on the form: the oral solution must be measured with a calibrated device and is not to be mixed with other liquids. Extended-release capsules must be swallowed whole or sprinkled on soft food, but must not be crushed or chewed.

Population-Specific Rules

Mandatory dose adjustments apply to specific patient groups. For individuals with severe renal impairment (creatinine clearance of 5–29 mL/min), the maximum daily intake is restricted to 10 mg for the immediate-release formulation. Additionally, the overall treatment protocol requires that a physician experienced in managing the underlying condition initiate and supervise the therapy, with the necessity of continued long-term use subject to regular reassessment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Memorel

Evidence for Moderate-to-Severe Alzheimer's Dementia (Monotherapy)

Research exploring Memorel (Memantine Hydrochloride) primarily was evaluated in patients with moderate-to-severe cognitive impairment linked to Alzheimer's disease. The foundational evidence comes from short-term randomized controlled trials (RCTs) that compared Memorel to an inactive substance (placebo). These studies were studied for populations of older adults, and research examined outcomes related to changes in their cognitive function and their daily functional capacity.

Studies reported measurements of cognitive and functional scores following the administration of Memorel over periods generally lasting up to six months. The measured changes on the standardized scales were observed in some studies to be modest. While the evidence base is extensive for this severity, the follow-up durations were limited, meaning there is limited information for long-term outcomes.

Evidence for Use as Add-on Therapy

Studies was studied for a scenario where Memorel is given to patients who are already taking a cholinesterase inhibitor. Researchers conducted randomized trials where patients maintained their existing treatment while either Memorel or a placebo was added to their regimen.

Studies reported measurements on cognitive and functional scales in the combined therapy group that were observed to differ from those recorded in the group receiving placebo. Pooled analyses described that the combined therapy group was associated with modest differences in patient status measurements over the typical six-month trial duration. Certainty remains low regarding the long-term patterns of continuing this combined therapy.

Evidence Gaps and Areas of Uncertainty

The primary research authorized by regulators focuses on moderate-to-severe disease. Studies explored the medicine's potential in patients with milder forms of cognitive impairment, but clinical trial reports concerning this use presented inconsistent findings across various outcome measures. Because of these varied reports, the consistency of findings remains limited concerning use in milder forms of dementia. Furthermore, the changes measured in the clinical trials were described by researchers as small, and comparative evidence is lacking for trials directly comparing Memorel against every other medication used for similar conditions.

Key Studies & References

National Institute for Health and Care Excellence (NICE) Guideline: Dementia assessment, management and support for people living with dementia and their carers

Frequently Asked Questions (FAQ)

Common questions about Memorel (FAQ)

Q: Why do people take Memorel if it doesn't cure the underlying condition?

Memorel is defined in regulatory documents as a medicine for the symptomatic management of the underlying condition, indicating its role is to address symptoms rather than halt or reverse the disease course. Studies have examined its effects primarily through measurements of modest changes on standardized cognitive and functional scales.

Q: How quickly should I expect to notice any difference after starting Memorel?

Regulatory documentation describes a structured dose-adjustment process, or titration, that typically lasts several weeks to reach the final maintenance dose. The clinical trials used to evaluate the drug's intended effects were generally conducted over periods lasting up to six months.

Q: Does Memorel start working right away, or does it take a few weeks?

The official treatment protocol requires a gradual increase in dose over several weeks to reach the intended maintenance dose. This titration process is designed to improve tolerability. The medicine is intended for continuous, long-term use, rather than offering immediate, short-term relief.

Q: What is the longest period of time a person can safely use Memorel?

Official guidelines indicate that the medicine is intended for continued long-term use. However, the necessity of maintaining the therapy is subject to regular reassessment by the supervising physician.

Q: Is it okay to take Memorel only when I feel like I need it?

The official administration protocol requires a structured, gradual increase to a target maintenance dose. Because of this required titration and its stated purpose for long-term use, it is not intended to be taken intermittently or only when a person feels they need it.

Q: What happens if I forget to take Memorel for a day or two?

Official guidance on missed doses describes a protocol where if a single dose is missed, a patient is instructed not to double up on the subsequent dose. The following dose is then taken at the regularly scheduled time.

Q: Does Memorel interact negatively with alcohol consumption?

Official product information describes that combining Memorel with alcohol may increase the risk of specific central nervous system-related side effects, such as feelings of dizziness or fainting. Regulatory documentation indicates these effects may be enhanced when alcohol is consumed.

Q: Does Memorel make people gain or lose weight?

According to regulatory safety documentation, both increased weight and decreased weight have been listed in the Common category of adverse reactions. This means that these changes occurred in clinical trials in 1% to less than 10% of patients who were studied.

Q: How often do people stop taking Memorel because of side effects?

Data from clinical trials indicated that the rate of discontinuation of treatment due to adverse reactions was similar between the group receiving Memorel and the group receiving a placebo (inactive substance). Specifically, the rates were reported as 10.1% for Memorel and 11.5% for placebo.

Q: Is Memorel safe for older adults over 75?

The medicine is approved for use in all adults and has been extensively studied in the elderly population as the primary focus of clinical research. Official guidelines recommend a standard maintenance dose for individuals over 65 years of age.

Q: Is Memorel safe to use during pregnancy or while breastfeeding?

Official information describes that use during pregnancy is generally restricted to circumstances where the potential benefit justifies the potential risk to the fetus. It is not known whether the active substance is excreted in human milk, and its use is therefore subject to caution when considering administration to a nursing mother.

Q: Why is Memorel not recommended for people with certain heart conditions?

Official product information lists serious but uncommon adverse reactions such as cardiac failure and venous thromboembolism (blood clots) as potential risks. Such risks necessitate caution, and specific monitoring may be described in regulatory warnings for patients with pre-existing cardiovascular conditions.

Q: Are there long-term studies on the safety of Memorel?

Research evidence for efficacy primarily comes from short-term trials, and official documents note limited information on long-term outcomes beyond approximately six months. However, the active substance has been used in clinical practice for over ten years in some regions, with safety continuously monitored through required post-marketing surveillance.

Q: If I am already on blood pressure medicine, can I still take Memorel?

The regulatory interaction profile specifically notes a potential effect on hydrochlorothiazide, a common blood pressure medication, which may lead to reduced serum levels when taken with Memorel. The official product information for other specific blood pressure medicines is not detailed in the same way.

Q: How often are follow-up appointments necessary when on Memorel?

Official administration guidelines specify that a physician must initiate and supervise the therapy. Furthermore, the necessity of continuing long-term use is subject to regular reassessment by the supervising healthcare professional.

Q: Is it normal to feel a bit restless when starting Memorel?

While 'restlessness' may not be explicitly listed among the most frequent side effect categories, related central nervous system effects are reported in official safety documentation. These include confusion and agitation, which have been listed as uncommon adverse reactions in clinical trials.

Q: Can Memorel affect my ability to drive or operate machinery?

Official safety documentation notes that Memorel has been observed to have a minor to moderate influence on the ability to drive or operate machinery. This is due to its potential central nervous system effects, which may include confusion and dizziness. The official documentation includes warnings related to assessing one's fitness to drive or operate machinery.

Q: Is Memorel available over the counter, or is it prescription-only?

Official regulatory labeling clearly classifies Memorel as a prescription-only medicine (Rx Only). It cannot be legally dispensed without a valid prescription from a licensed healthcare professional.

Q: Can children or adolescents use Memorel?

Use in children and adolescents under 18 years of age is not recommended. This decision is based on a lack of sufficient regulatory data to establish both the safety and efficacy of the medicine for this population.

Q: What are the typical warnings given to patients before starting Memorel?

The official product information outlines several warnings for healthcare professionals to consider before starting treatment. These include a known hypersensitivity to the drug and conditions that may alter drug exposure, such as severe kidney (renal) or liver (hepatic) impairment. Caution is also advised regarding the use of other N-methyl-D-aspartate (NMDA) antagonists and for patients with a history of seizures.

How should Memorel be stored and disposed of?

Storage and Disposal Requirements

Memorel (memantine hydrochloride) must be stored at Controlled Room Temperature to maintain product stability. The required storage temperature is 25 C (77 F), with a permitted variation range between 15 C to 30 C (59 F to 86 F), as defined by regulatory guidelines. The medicine must not be used past the printed expiry date (EXP).

All medicinal products, including Memorel, must be kept strictly out of the sight and reach of children.

For disposal, unused or expired Memorel should not be disposed of in household waste or wastewater.

The unused product must be discarded in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.